Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Adaptive Immune Response Stimulated with TLR8 and Dual TLR7/TLR8 Agonists

Technology #20160410-20170196

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Toll Like ReceptorsImmune Response
Categories
Researchers
Sunil David, MD, PhD
Professor, Medicinal Chemistry
External Link (www.pharmacy.umn.edu)
Alex Salyer
Research Specialist, Medicinal Chemistry
Mallesh Beesu
Researcher, Medicinal Chemistry
Michael Brush
Researcher, Medicinal Chemistry
Kathryn Trautman
Researcher, Medicinal Chemistry
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

Provisional Patent Application Filed
Publications
Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines
Journal of Medicinal Chemistry, 2017, 60 (5), pp 2084–2098

Augments Innate Immune Response

Highly potent and selective TLR8 and dual TLR7/TLR8 agonists can stimulate human adaptive immune response.

  • TLR8 agonist: 5-(4-Aminobutyl)-N4-butyl-6-methylpyrimidine-2,4-diamine dihydrochloride is a novel potent and highly selective TLR8 agonist.
  • TLR7/TLR8 agonist: N4-butyl-6-methyl-5-(3-morpholinopropyl) pyrimidine-2,4-diamine is a very potent dual TLR7/TLR8 agonist.

These compounds hold potential as vaccine adjuvants that could augment innate immune response against inflammatory, microbial and/or viral diseases as well as cancer.

Superior Adjuvant Properties

Toll-like receptors (TLRs) play a crucial role in host defense, inflammation, and immune response, and significant efforts have gone into development of potent TLR agonists. Adjuvants help antigens elicit an early, high and long-lasting immune response, allowing more robust responses to vaccines and reducing vaccine production costs. In these newly discovered agonists, potency at TLR7 correlates with IFN-alpha/beta production in human blood, whereas IFN-gamma and TNF-α induction are largely TLR8-dependent. Dual TLR7/TLR8 agonists markedly upregulate CD80 expression in multiple dendritic cell subsets, providing insight into the immunological basis for the superior adjuvantic properties of such innate immune stimuli. This lead compound induces Th1-biasing interferon gamma and IL-12 in human blood cells but does not induce significant levels of IL-1beta, IL-6 or IL-8 (proinflammatory cytokines).

BENEFITS AND FEATURES:

  • Stimulate human adaptive immune response
  • Vaccine adjuvants could augment innate immune response against inflammatory, microbial and/or viral diseases as well as cancer
  • Pure TLR-8 agonists are especially important as vaccines adjuvants for newborns as well as the elderly as their bodies do not mount adequate immune response

APPLICATIONS:

  • Vaccine adjuvants against allergic, viral and microbial diseases
  • Immunostimulant/immunotherapy against cancer
  • Scientific study of how TLR-8 receptors augment immune response; may lead to more efficient therapeutics
  • Immunoassays
  • Ex vivo experiments

Phase of Development:
In vitro data.
20170196: Compounds generated and tested in vitro for inducing various cytokines
20160410: Lead compound generated and tested in vitro for inducing various cytokines

Interested in Licensing?
The University relies on industry partners to scale up technologies to large enough production capacity for commercial purposes. The license is available for this technology and would be for the sale, manufacture or use of products claimed by the issued patents. Please contact Kevin Anderson to share your business needs and technical interest in this immune response technology and if you are interested in licensing the technology for further research and development.